Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion.


Journal

Cellular & molecular biology letters
ISSN: 1689-1392
Titre abrégé: Cell Mol Biol Lett
Pays: England
ID NLM: 9607427

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 12 01 2024
accepted: 14 06 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 3 7 2024
Statut: epublish

Résumé

We have previously identified an unsuspected role for GJB3 showing that the deficiency of this connexin protein induces aneuploidy in human and murine cells and accelerates cell transformation as well as tumor formation in xenograft models. The molecular mechanisms by which loss of GJB3 leads to aneuploidy and cancer initiation and progression remain unsolved. GJB3 expression levels were determined by RT-qPCR and Western blot. The consequences of GJB3 knockdown on genome instability were assessed by metaphase chromosome counting, multinucleation of cells, by micronuclei formation and by the determination of spindle orientation. Interactions of GJB3 with α-tubulin and F-actin was analyzed by immunoprecipitation and immunocytochemistry. Consequences of GJB3 deficiency on microtubule and actin dynamics were measured by live cell imaging and fluorescence recovery after photobleaching experiments, respectively. Immunohistochemistry was used to determine GJB3 levels on human and murine bladder cancer tissue sections. Bladder cancer in mice was chemically induced by BBN-treatment. We find that GJB3 is highly expressed in the ureter and bladder epithelium, but it is downregulated in invasive bladder cancer cell lines and during tumor progression in both human and mouse bladder cancer. Downregulation of GJB3 expression leads to aneuploidy and genomic instability in karyotypically stable urothelial cells and experimental modulation of GJB3 levels alters the migration and invasive capacity of bladder cancer cell lines. Importantly, GJB3 interacts both with α-tubulin and F-actin. The impairment of these interactions alters the dynamics of these cytoskeletal components and leads to defective spindle orientation. We conclude that deregulated microtubule and actin dynamics have an impact on proper chromosome separation and tumor cell invasion and migration. Consequently, these observations indicate a possible role for GJB3 in the onset and spreading of bladder cancer and demonstrate a molecular link between enhanced aneuploidy and invasive capacity cancer cells during tumor cell dissemination.

Sections du résumé

BACKGROUND BACKGROUND
We have previously identified an unsuspected role for GJB3 showing that the deficiency of this connexin protein induces aneuploidy in human and murine cells and accelerates cell transformation as well as tumor formation in xenograft models. The molecular mechanisms by which loss of GJB3 leads to aneuploidy and cancer initiation and progression remain unsolved.
METHODS METHODS
GJB3 expression levels were determined by RT-qPCR and Western blot. The consequences of GJB3 knockdown on genome instability were assessed by metaphase chromosome counting, multinucleation of cells, by micronuclei formation and by the determination of spindle orientation. Interactions of GJB3 with α-tubulin and F-actin was analyzed by immunoprecipitation and immunocytochemistry. Consequences of GJB3 deficiency on microtubule and actin dynamics were measured by live cell imaging and fluorescence recovery after photobleaching experiments, respectively. Immunohistochemistry was used to determine GJB3 levels on human and murine bladder cancer tissue sections. Bladder cancer in mice was chemically induced by BBN-treatment.
RESULTS RESULTS
We find that GJB3 is highly expressed in the ureter and bladder epithelium, but it is downregulated in invasive bladder cancer cell lines and during tumor progression in both human and mouse bladder cancer. Downregulation of GJB3 expression leads to aneuploidy and genomic instability in karyotypically stable urothelial cells and experimental modulation of GJB3 levels alters the migration and invasive capacity of bladder cancer cell lines. Importantly, GJB3 interacts both with α-tubulin and F-actin. The impairment of these interactions alters the dynamics of these cytoskeletal components and leads to defective spindle orientation.
CONCLUSION CONCLUSIONS
We conclude that deregulated microtubule and actin dynamics have an impact on proper chromosome separation and tumor cell invasion and migration. Consequently, these observations indicate a possible role for GJB3 in the onset and spreading of bladder cancer and demonstrate a molecular link between enhanced aneuploidy and invasive capacity cancer cells during tumor cell dissemination.

Identifiants

pubmed: 38956497
doi: 10.1186/s11658-024-00609-2
pii: 10.1186/s11658-024-00609-2
doi:

Substances chimiques

Tubulin 0
Actins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : GU569/6-1
Organisme : Deutsche Forschungsgemeinschaft
ID : EI792/7-1
Organisme : Wilhelm Sander-Stiftung
ID : 2019.038.1

Informations de copyright

© 2024. The Author(s).

Références

Meena JK, Cerutti A, Beichler C, Morita Y, Bruhn C, Kumar M, et al. Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion. EMBO J. 2015;34(10):1371–84.
pubmed: 25820263 pmcid: 4491997 doi: 10.15252/embj.201490070
Njeru SN, Kraus J, Meena JK, Lechel A, Katz SF, Kumar M, et al. Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor. Oncogene. 2020;39(7):1445–65.
pubmed: 31659255 doi: 10.1038/s41388-019-1073-2
Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem. 1996;238(1):1–27.
pubmed: 8665925 doi: 10.1111/j.1432-1033.1996.0001q.x
Meşe G, Richard G, White TW. Gap junctions: basic structure and function. J Invest Dermatol. 2007;127(11):2516–24.
pubmed: 17934503 doi: 10.1038/sj.jid.5700770
Krutovskikh V, Yamasaki H. The role of gap junctional intercellular communication (GJIC) disorders in experimental and human carcinogenesis. Histol Histopathol. 1997;12(3):761–8.
pubmed: 9225159
Tang C, Chen X, Chi J, Yang D, Liu S, Liu M, et al. Pathogenic Cx31 is un/misfolded to cause skin abnormality via a Fos/JunB-mediated mechanism. Hum Mol Genet. 2015;24(21):6054–65.
pubmed: 26251042 doi: 10.1093/hmg/ddv317
Yuan Y, You Y, Huang D, Cui J, Wang Y, Wang Q, et al. Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China. J Transl Med. 2009;7:79.
pubmed: 19744334 pmcid: 2754984 doi: 10.1186/1479-5876-7-79
Oyamada M, Oyamada Y, Takamatsu T. Regulation of connexin expression. Biochim Biophys Acta. 2005;1719(1–2):6–23.
pubmed: 16359940 doi: 10.1016/j.bbamem.2005.11.002
Geimonen E, Jiang W, Ali M, Fishman GI, Garfield RE, Andersen J. Activation of protein kinase C in human uterine smooth muscle induces connexin-43 gene transcription through an AP-1 site in the promoter sequence. J Biol Chem. 1996;271(39):23667–74.
pubmed: 8798588 doi: 10.1074/jbc.271.39.23667
Britz-Cunningham SH, Shah MM, Zuppan CW, Fletcher WH. Mutations of the connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med. 1995;332(20):1323–9.
pubmed: 7715640 doi: 10.1056/NEJM199505183322002
Chaible LM, Sanches DS, Cogliati B, Mennecier G, Dagli ML. Delayed osteoblastic differentiation and bone development in Cx43 knockout mice. Toxicol Pathol. 2011;39(7):1046–55.
pubmed: 21934140 doi: 10.1177/0192623311422075
Gao Y, Zhang Q, Zhang S, Yang L, Liu Y, Liu Y, et al. A connexin gene (GJB3) mutation in a chinese family with erythrokeratodermia variabilis, ichthyosis and nonsyndromic hearing loss: case report and mutations update. Front Genet. 2022;13: 797124.
pubmed: 35677558 pmcid: 9168653 doi: 10.3389/fgene.2022.797124
Aliazami F, Farhud D, Zarif-Yeganeh M, Salehi S, Hosseinipour A, Sasanfar R, et al. Gjb3 gene mutations in non-syndromic hearing loss of bloch, kurd, and turkmen ethnicities in Iran. Iran J Public Health. 2020;49(11):2128–35.
pubmed: 33708733 pmcid: 7917519
Elzarrad MK, Haroon A, Willecke K, Dobrowolski R, Gillespie MN, Al-Mehdi AB. Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. BMC Med. 2008;6:20.
pubmed: 18647409 pmcid: 2492868 doi: 10.1186/1741-7015-6-20
Zhang YW, Morita I, Ikeda M, Ma KW, Murota S. Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene. 2001;20(31):4138–49.
pubmed: 11464280 doi: 10.1038/sj.onc.1204563
Qin H, Shao Q, Curtis H, Galipeau J, Belliveau DJ, Wang T, et al. Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J Biol Chem. 2002;277(32):29132–8.
pubmed: 12042301 doi: 10.1074/jbc.M200797200
Aasen T, Leithe E, Graham SV, Kameritsch P, Mayán MD, Mesnil M, et al. Connexins in cancer: bridging the gap to the clinic. Oncogene. 2019;38(23):4429–51.
pubmed: 30814684 pmcid: 6555763 doi: 10.1038/s41388-019-0741-6
Naoi Y, Miyoshi Y, Taguchi T, Kim SJ, Arai T, Tamaki Y, et al. Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. Breast Cancer Res Treat. 2007;106(1):11–7.
pubmed: 17203385 doi: 10.1007/s10549-006-9465-8
Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, et al. Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Res Treat. 2019;174(1):93–102.
pubmed: 30474779 doi: 10.1007/s10549-018-5063-9
Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, et al. Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide. Cancer Res. 2016;76(1):139–49.
pubmed: 26542214 doi: 10.1158/0008-5472.CAN-15-1286
Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, et al. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget. 2017;8(13):21281–9.
pubmed: 28177904 pmcid: 5400583 doi: 10.18632/oncotarget.15068
Zhang D, Chen C, Li Y, Fu X, Xie Y, Li Y, et al. Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med. 2012;16(5):1047–59.
pubmed: 21777377 pmcid: 4365884 doi: 10.1111/j.1582-4934.2011.01389.x
Grossman HB, Liebert M, Lee IW, Lee SW. Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer Res. 1994;54(11):3062–5.
pubmed: 8187096
Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, et al. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. J Clin Pathol. 2015;68(10):819–24.
pubmed: 26251520 doi: 10.1136/jclinpath-2015-202898
Campanella R, Russo A, Plaja S, Bazan V, Pavone C, Corselli G, et al. Study of cellular DNA content by flow cytometry in primary bladder carcinomas. Significance of monoclonal and multiclonal varieties of DNA aneuploidy. Eur Urol. 1992;21(1):58–63.
pubmed: 1606985 doi: 10.1159/000474802
Jakobsen A, Mommsen S, Olsen S. Characterization of ploidy level in bladder tumors and selected site specimens by flow cytometry. Cytometry. 1983;4(2):170–3.
pubmed: 6628139 doi: 10.1002/cyto.990040211
Deliveliotis C, Georgoulakis J, Skolarikos A, Trakas N, Varkarakis J, Albanis S, et al. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder. Urol Res. 2005;33(1):39–43.
pubmed: 15258707 doi: 10.1007/s00240-004-0439-1
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
pubmed: 30350310 doi: 10.1002/ijc.31937
Florl AR, Schulz WA. Chromosomal instability in bladder cancer. Arch Toxicol. 2008;82(3):173–82.
pubmed: 18253719 doi: 10.1007/s00204-008-0280-3
Wang X, Liu J, Azoitei A, Eiseler T, Meessen S, Jiang W, et al. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics. Cell Mol Life Sci. 2023;80(10):299.
pubmed: 37740130 pmcid: 10516806 doi: 10.1007/s00018-023-04959-6
Wang W, Zheng X, Azoitei A, John A, Zengerling F, Wezel F, et al. The role of TKS5 in chromosome stability and bladder cancer progression. Int J Mol Sci. 2022;23(22):14283.
pubmed: 36430759 pmcid: 9698602 doi: 10.3390/ijms232214283
Meessen S, Rother J, Zheng X, Eckstein M, Kriegmair MC, Hernandez D, et al. Establishment of real-time multispectral imaging for the detection of bladder cancer using a preclinical in vivo model. Bladder Cancer. 2020;6(3):285–94.
doi: 10.3233/BLC-200314
Schneider L, Liu J, Zhang C, Azoitei A, Meessen S, Zheng X, et al. The role of interleukin-1-receptor-antagonist in bladder cancer cell migration and invasion. Int J Mol Sci. 2021;22(11):5875.
pubmed: 34070905 pmcid: 8198563 doi: 10.3390/ijms22115875
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, et al. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000162 .
doi: 10.1136/jitc-2019-000162 pubmed: 33023982 pmcid: 7539609
Weyerer V, Stoehr R, Bertz S, Lange F, Geppert CI, Wach S, et al. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol. 2021;39(11):4011–9.
pubmed: 34259899 pmcid: 8571152 doi: 10.1007/s00345-021-03788-1
Stolz A, Ertych N, Bastians H. A phenotypic screen identifies microtubule plus end assembly regulators that can function in mitotic spindle orientation. Cell Cycle. 2015;14(6):827–37.
pubmed: 25590964 pmcid: 4614948 doi: 10.1080/15384101.2014.1000693
Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. 2017;17(1):49–59.
pubmed: 27916979 doi: 10.1038/nri.2016.123
Wezel F, Lustig J, Azoitei A, Liu J, Meessen S, Najjar G, et al. Grainyhead-like 3 influences migration and invasion of urothelial carcinoma cells. Int J Mol Sci. 2021;22(6):2959.
pubmed: 33803949 pmcid: 8000182 doi: 10.3390/ijms22062959
Díaz B. Invadopodia detection and gelatin degradation assay. Bioprotocol. 2013. https://doi.org/10.21769/BioProtoc.997 .
doi: 10.21769/BioProtoc.997
Weeber F, Becher A, Seibold T, Seufferlein T, Eiseler T. Concerted regulation of actin polymerization during constitutive secretion by cortactin and PKD2. J Cell Sci. 2019. https://doi.org/10.1242/jcs.232355 .
doi: 10.1242/jcs.232355 pubmed: 31727638
Eiseler T, Hausser A, De Kimpe L, Van Lint J, Pfizenmaier K. Protein kinase D controls actin polymerization and cell motility through phosphorylation of cortactin. J Biol Chem. 2010;285(24):18672–83.
pubmed: 20363754 pmcid: 2881792 doi: 10.1074/jbc.M109.093880
Ertych N, Stolz A, Stenzinger A, Weichert W, Kaulfuß S, Burfeind P, et al. Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nat Cell Biol. 2014;16(8):779–91.
pubmed: 24976383 pmcid: 4389786 doi: 10.1038/ncb2994
Petzoldt JL, Leigh IM, Duffy PG, Sexton C, Masters JR. Immortalisation of human urothelial cells. Urol Res. 1995;23(6):377–80.
pubmed: 8788275 doi: 10.1007/BF00698738
Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28(16):2660–7.
pubmed: 20421545 doi: 10.1200/JCO.2009.25.0977
Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. 2018;37(14):1911–25.
pubmed: 29367767 pmcid: 5886988 doi: 10.1038/s41388-017-0099-6
Bisaria A, Hayer A, Garbett D, Cohen D, Meyer T. Membrane-proximal F-actin restricts local membrane protrusions and directs cell migration. Science. 2020;368(6496):1205–10.
pubmed: 32527825 pmcid: 8283920 doi: 10.1126/science.aay7794
Legátová A, Pelantová M, Rösel D, Brábek J, Škarková A. The emerging role of microtubules in invasion plasticity. Front Oncol. 2023;13:1118171.
pubmed: 36860323 pmcid: 9969133 doi: 10.3389/fonc.2023.1118171
Vasudevan A, Baruah PS, Smith JC, Wang Z, Sayles NM, Andrews P, et al. Single-chromosomal gains can function as metastasis suppressors and promoters in colon cancer. Dev Cell. 2020;52(4):413-28.e6.
pubmed: 32097652 pmcid: 7354079 doi: 10.1016/j.devcel.2020.01.034
Lu H, Zhao Q, Jiang H, Zhu T, Xia P, Seffens W, et al. Characterization of ring-like F-actin structure as a mechanical partner for spindle positioning in mitosis. PLoS ONE. 2014;9(10): e102547.
pubmed: 25299690 pmcid: 4191959 doi: 10.1371/journal.pone.0102547
Welf ES, Miles CE, Huh J, Sapoznik E, Chi J, Driscoll MK, et al. Actin-membrane release initiates cell protrusions. Dev Cell. 2020;55(6):723-36 e8.
pubmed: 33308479 pmcid: 7908823 doi: 10.1016/j.devcel.2020.11.024
Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377(6549):539–44.
pubmed: 7566154 doi: 10.1038/377539a0
Nagano M, Hoshino D, Koshikawa N, Akizawa T, Seiki M. Turnover of focal adhesions and cancer cell migration. Int J Cell Biol. 2012;2012: 310616.
pubmed: 22319531 pmcid: 3272802 doi: 10.1155/2012/310616
Jüschke C, Xie Y, Postiglione MP, Knoblich JA. Analysis and modeling of mitotic spindle orientations in three dimensions. Proc Natl Acad Sci USA. 2014;111(3):1014–9.
pubmed: 24381158 doi: 10.1073/pnas.1314984111
Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112(4):453–65.
pubmed: 12600310 doi: 10.1016/S0092-8674(03)00120-X
Etienne-Manneville S. Microtubules in cell migration. Annu Rev Cell Dev Biol. 2013;29:471–99.
pubmed: 23875648 doi: 10.1146/annurev-cellbio-101011-155711
Pimm ML, Henty-Ridilla JL. New twists in actin-microtubule interactions. Mol Biol Cell. 2021;32(3):211–7.
pubmed: 33507109 pmcid: 8098829 doi: 10.1091/mbc.E19-09-0491
Garcin C, Straube A. Microtubules in cell migration. Essays Biochem. 2019;63(5):509–20.
pubmed: 31358621 pmcid: 6823166 doi: 10.1042/EBC20190016
Ogawa K, Pitchakarn P, Suzuki S, Chewonarin T, Tang M, Takahashi S, et al. Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci. 2012;103(5):860–7.
pubmed: 22320152 pmcid: 7659240 doi: 10.1111/j.1349-7006.2012.02228.x
Vanderpuye OA, Bell CL, Murray SA. Redistribution of connexin 43 during cell division. Cell Biol Int. 2016;40(4):387–96.
pubmed: 26724787 pmcid: 9374566 doi: 10.1002/cbin.10576
Ambrosi C, Ren C, Spagnol G, Cavin G, Cone A, Grintsevich EE, et al. Connexin43 forms supramolecular complexes through non-overlapping binding sites for Drebrin, Tubulin, and ZO-1. PLoS ONE. 2016;11(6): e0157073.
pubmed: 27280719 pmcid: 4900556 doi: 10.1371/journal.pone.0157073
Duijf PH, Benezra R. The cancer biology of whole-chromosome instability. Oncogene. 2013;32(40):4727–36.
pubmed: 23318433 doi: 10.1038/onc.2012.616
Orr B, Compton DA. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front Oncol. 2013;3:164.
pubmed: 23825799 pmcid: 3695391 doi: 10.3389/fonc.2013.00164
Conery AR, Harlow E. High-throughput screens in diploid cells identify factors that contribute to the acquisition of chromosomal instability. Proc Natl Acad Sci USA. 2010;107(35):15455–60.
pubmed: 20713694 pmcid: 2932617 doi: 10.1073/pnas.1010627107

Auteurs

Junnan Liu (J)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Department of Urology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Xue Wang (X)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Wencheng Jiang (W)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Anca Azoitei (A)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Tim Eiseler (T)

Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

Markus Eckstein (M)

Institute of Pathology, Friedrich-Alexander University, Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology, Friedrich-Alexander University, Erlangen, Germany.

Stephan Stilgenbauer (S)

Department of Internal Medicine III, Ulm University, Ulm, Germany.

Mohamed Elati (M)

CANTHER, ONCOLille Institute, University of Lille, CNRS, UMR 1277, Inserm U9020, 59045, Lille Cedex, France.

Meike Hohwieler (M)

Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.

Alexander Kleger (A)

Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.

Axel John (A)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Felix Wezel (F)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Friedemann Zengerling (F)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Christian Bolenz (C)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany.

Cagatay Günes (C)

Department of Urology, Ulm University Hospital, Helmholtzstr. 10, 89081, Ulm, Germany. Cagatay.guenes@uniklinik-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH